PHIO vs PHVS

Phio Pharmaceuticals Corp. vs Pharvaris N.V. — Valuation Comparison 2026

PHIO

Biotechnology
Phio Pharmaceuticals Corp.
Quality
3.7
out of 10
Value Trap
39
LOW
Price
$1.14
Last close
Models
7/13
Active
VS

PHVS

Biotechnology
Pharvaris N.V.
Quality
3.9
out of 10
Value Trap
6
SAFE
Price
$29.86
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType PHIO Fair ValuePHIO Upside PHVS Fair ValuePHVS Upside
Bayesian DCF Intrinsic $1.11 -2.8% $10.81 -63.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.64 +43.8% $4.54 -84.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PHIO vs PHVS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PHIO vs PHVS — Which Stock Is More Undervalued?

PHVS scores higher with a 3.9/10 quality rating vs PHIO's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Phio Pharmaceuticals Corp. (PHIO) and Pharvaris N.V. (PHVS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PHIO currently trades at $1.14 with a QOC of 3.7/10, while PHVS trades at $29.86 with a QOC of 3.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).